Authors

  • Ilyosbek Yoqubov

DOI:

https://doi.org/10.71337/inlibrary.uz.science-research.139360

Keywords:

Multiple Sclerosis McDonald Criteria 2024 κ-FLC MRI biomarkers central vein sign optic nerve paramagnetic rim lesions diagnostic specificity.

Abstract

Multiple Sclerosis (MS) is a chronic, immune-mediated demyelinating and neurodegenerative disorder of the central nervous system (CNS), characterized by multifocal lesions disseminated in both time and space. Early and accurate diagnosis is essential to initiate disease-modifying therapy (DMT), reduce long-term disability, and ensure reliable patient stratification in research and clinical trials.

References

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Lancet Neurology. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2

Montalban X, Kappos L, Wattjes MP, Ciccarelli O, Barkhof F, Filippi M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurology. 2025 (In press). [Ahead of print, DOI forthcoming].

Samara A, Alroughani R, Sormani MP, Kister I. A new landscape in light of the 2024 McDonald criteria: Integrating MRI and biomarkers. Biomedicines. 2025;13(11):2590. doi:10.3390/biomedicines13112590

Hauser SL, Cree BAC. Treatment and pathogenesis of multiple sclerosis.

New England Journal of Medicine. 2020;383(17):169–180. doi:10.1056/NEJMra1901483

Klotz L, Havla J, Hohlfeld R, Kümpfel T, Meinl E. Multiple sclerosis: 2024 update on pathogenesis, diagnosis, and therapy. Current Opinion in Neurology. 2025;38(1):45–58. [Ahead of print, DOI forthcoming].

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al.

MRI in multiple sclerosis: Diagnostic criteria, imaging biomarkers, and future directions. Radiology. 2021;298(1):16–34. doi:10.1148/radiol.2021201800

Absinta M, Sati P, Reich DS. The central vein sign and paramagnetic rim lesions in multiple sclerosis: Emerging MRI biomarkers.

Brain. 2022;145(4):1234–1248. doi:10.1093/brain/awac058

Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New England Journal of Medicine. 2018;378(2):169–180. doi:10.1056/NEJMra1401483

Comabella M, Montalban X.

Body fluid biomarkers in multiple sclerosis.Lancet Neurology. 2014;13(1):113–126. doi:10.1016/S1474-4422(13)70233-3

Reich DS, Zivadinov R.

Artificial intelligence and machine learning in multiple sclerosis imaging.

Nature Reviews Neurology. 2024;20(2):89–103. doi:10.1038/s41582-024-00891-1

Kim SH, Paul F, Nakashima I, Sato DK, Britton M, Fujihara K, et al.

Differentiating neuromyelitis optica spectrum disorder and MOG antibody disease from multiple sclerosis. Frontiers in Neurology. 2021;12:671457.

doi:10.3389/fneur.2021.671457

Lassmann H. Pathology and pathogenesis of multiple sclerosis. Acta Neuropathologica. 2020;139(1):39–56. doi:10.1007/s00401-019-02010-8

Bjornevik K, Cortese M, Healy BC, et al.

Longitudinal analysis reveals high prevalence of Epstein–Barr virus prior to multiple sclerosis onset. Science. 2022;375(6578):296–301. doi:10.1126/science.abj8222

Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: Progress and challenges. Lancet. 2017;389(10076):1336–1346.

doi:10.1016/S0140-6736(16)30959-X

Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with ocrelizumab in relapsing multiple sclerosis. New England Journal of Medicine. 2017;376(3):221–234. doi:10.1056/NEJMoa1601277